Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study.

ABSTRACT:

Background

The N-methyl-D-aspartate antagonist ketamine has rapid onset antidepressant activity in treatment-resistant depression (TRD).

Aims

To evaluate mood rating, safety and tolerability data from patients with TRD treated with ketamine and the psychoactive control fentanyl, as part of a larger study to explore EEG biomarkers associated with mood response.

Methods

We evaluated the efficacy and safety of intramuscular racemic ketamine in 25 patients with TRD, using a double-blind active-controlled randomized crossover design. Ketamine doses were 0.5 and 1 mg/kg, and the psychoactive control was fentanyl 50 mcg, given at weekly intervals.

Results/outcomes

Within 1 h of ketamine dosing, patients reported reduced depression and anxiety ratings, which persisted

SUBMITTER: Glue P 

PROVIDER: S-EPMC10863359 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature